Health Catalyst 3Q 2026: Revenue $56.28M, EPS $0.53 — 10-Q Summary

Health Catalyst reported 3Q 2026 revenue of $56.28M, down 26.3% YoY, and net income of $40.5M, up 282.2% YoY. The decline was attributed to the Vitalware divestiture, migration churn, and exits from lower-margin arrangements. Earnings were boosted by a gain on the Vitalware sale.

Original reporting
Published Nov 5, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Health Catalyst 3Q 2026: Revenue $56.28M, EPS $0.53 — 10-Q Summary — source image
Decision brief

The 30-second read

$HCATNeutralMed
01

Why it matters

The earnings release provides fresh data for traders; the mix of declining core revenue and a non‑recurring gain creates uncertainty about future earnings trajectory.

02

Market read

Primary earnings disclosure for a micro‑cap health‑tech company; new numbers may prompt short‑term trading activity.

03

What to watch

Restructuring cost reductions and potential future deals are not reflected in the current numbers.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

Health Catalyst filed its Q3 2026 10‑Q, highlighting a revenue decline driven by divestitures and churn, offset by a one‑time gain.

Company-level read

Ticker impact

$HCATNeutralHigh confidence
Context

Health Catalyst reported Q3 2026 revenue of $56.28M, a 26.3% YoY decline and a net income gain driven by a $65.9M pre‑tax gain on the Vitalware divestiture.

Expected impact

potential downside as the revenue drop outweighs the gain from the Vitalware sale

Evidence & confidence

Revenue contraction signals weaker operating performance; the gain is non‑recurring, so investors may discount it.

Market effects

Health data analytics sector may see heightened scrutiny on revenue trends after this decline.

U.S. healthcare IT stocks could experience modest pressure.

Limited to investors focused on U.S. health‑tech micro‑caps.

Counterpoint

The Vitalware divestiture cash could fund strategic acquisitions, offering upside if redeployed effectively.

Key entities

  • Health Catalyst, Inc.

    U.S. health‑data analytics firm (ticker HCAT).

Related articles

$HCATMed

Health Catalyst Reports Third Quarter 2026 Results

Health Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Health Catalyst Reports Third Quarter 2026 Results SALT LAKE CITY, UT, November 5, 2026 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported finan

$HCATMedAI 8/10

Health Catalyst (HCAT) Q2 2026 Earnings Call Transcript

Health Catalyst (HCAT) reported Q2 2026 revenue of $70.5M, down 13% from $80.7M a year earlier. Technology revenue fell to $48.8M and professional services to $21.7M. The company completed the Vitalware divestiture for $147M cash and repaid about $160M of debt. FY2026 guidance: revenue $246M-$249M and adjusted EBITDA $18M-$18.5M.

$HCATHighAI 9/10

Why Health Catalyst (HCAT) Shares Are Trading Lower Today

Health Catalyst (NASDAQ: HCAT) shares fell 23.1% after the company issued a weak Q3 revenue forecast and cut its full-year outlook. It expects Q3 revenue of $55.5 million versus $70.49 million in Q2, and reduced 2026 revenue guidance to $247.5 million at the midpoint. Q2 revenue met expectations, but the outlook pressured the stock.

$HCATMedAI 8/10

M&A: Health Catalyst Closes $147M Sale of Vitalware to Med-Metrix

Health Catalyst, Inc. said it closed the July 31, 2026 sale of Vitalware, LLC to Med-Metrix, LLC. The divestiture generated $147M in total cash consideration, subject to adjustments. Health Catalyst plans to use proceeds and cash on hand to fully repay its credit facility, removing about $19M in annual GAAP interest expense, and to focus on its core healthcare intelligence and AI platform.